Mouse, Rat, Human Predicted to work with:
Horse, Chicken, Cow, Dog, Pig, Macaque monkey, Gorilla, Orangutan
Synthetic peptide corresponding to Human 68kDa Neurofilament/ NF-L aa 100-200 conjugated to keyhole limpet haemocyanin. (Peptide available as ab136173)
This antibody gave a positive signal in the following tissue lysates: Human Brain; Rat Cerebellum; Human Spinal Cord; Mouse Spinal Cord.
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
pH: 7.40 Preservative: 0.02% Sodium azide Constituent: PBS Note: Batches of this product that have a concentration < 1mg/ml may have BSA added as a stabilising agent. If you would like information about the formulation of a specific lot, please contact our scientific support team who will be happy to help.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use a concentration of 1 µg/ml. Detects a band of approximately 68 kDa (predicted molecular weight: 61 kDa).
Neurofilaments usually contain three intermediate filament proteins: L, M, and H which are involved in the maintenance of neuronal caliber.
Involvement in disease
Defects in NEFL are the cause of Charcot-Marie-Tooth disease type 1F (CMT1F) [MIM:607734]. CMT1F is a form of Charcot-Marie-Tooth disease, the most common inherited disorder of the peripheral nervous system. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathy or CMT1, and primary peripheral axonal neuropathy or CMT2. Neuropathies of the CMT1 group are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet. CMT1F is characterized by onset in infancy or childhood (range 1 to 13 years). Defects in NEFL are the cause of Charcot-Marie-Tooth disease type 2E (CMT2E) [MIM:607684]. CMT2E is an autosomal dominant form of Charcot-Marie-Tooth disease type 2. Neuropathies of the CMT2 group are characterized by signs of axonal regeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.
Belongs to the intermediate filament family.
The extra mass and high charge density that distinguish the neurofilament proteins from all other intermediate filament proteins are due to the tailpiece extensions. This region may form a charged scaffolding structure suitable for interaction with other neuronal components or ions.
O-glycosylated. Phosphorylated in the Head and Rod regions by the PKC kinase PKN1, leading to inhibit polymerization.
Light molecular weight neurofilament protein antibody
Neurofilament light antibody
Neurofilament light polypeptide 68kDa antibody
Neurofilament light polypeptide antibody
Neurofilament protein, light chain antibody
Neurofilament subunit NF L antibody
Neurofilament triplet L protein antibody
Western blot - Anti-68kDa Neurofilament / NF-L antibody (ab113854)
All lanes : Anti-68kDa Neurofilament / NF-L antibody (ab113854) at 1 µg/ml
Lane 1 : Human brain tissue lysate - total protein (ab29466) Lane 2 : Cerebellum Rat Tissue Lysate Lane 3 : Human spinal cord tissue lysate - total protein (ab29188) Lane 4 : Spinal Cord (Mouse) Tissue Lysate
Lysates/proteins at 10 µg per lane.
Secondary All lanes : Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution